Proleukin, a cancer treatment, has a price that can vary.
How much does a dose of Proleukin cost?
The cost of Proleukin can be significant, with some sources indicating prices around $3,600 to $3,900 per vial [1]. Given that a course of treatment may involve multiple vials, the total cost can escalate. For example, a specific patient's out-of-pocket cost for a treatment cycle was reported as $35,000 after insurance and patient assistance programs [2].
What factors influence Proleukin's price?
The price of Proleukin is influenced by several factors inherent to specialty pharmaceuticals. These include the extensive research and development costs, the complex manufacturing process, and the clinical trials required for approval. Furthermore, the drug's status as a unique or targeted therapy often commands a premium.
Are there financial assistance programs for Proleukin?
Yes, programs exist to help patients manage the cost of Proleukin. The manufacturer may offer patient assistance programs, and some charitable foundations also provide financial aid for cancer treatments. Insurance coverage plays a crucial role, but even with insurance, co-pays and deductibles can contribute to substantial patient out-of-pocket expenses [2].
How does Proleukin's cost compare to other melanoma treatments?
Proleukin, a high-dose interleukin-2 (IL-2) therapy, is one of several treatment options for metastatic melanoma. Other treatments include immunotherapies like checkpoint inhibitors (e.g., ipilimumab, nivolumab, pembrolizumab) and targeted therapies. While Proleukin offers a chance for durable remission, its administration is complex and associated with significant toxicity, which can also factor into overall treatment costs when considering hospitalization and supportive care [3]. Comparative pricing between these modalities is complex and depends on the specific drug, dosage, duration of treatment, and insurance reimbursement.
What is Proleukin and what is it used for?
Proleukin is a form of biologic therapy, specifically an immunotherapy, that uses a protein called interleukin-2 to stimulate the body's immune system to fight cancer [4]. It is approved for the treatment of metastatic renal cell carcinoma (kidney cancer) and metastatic melanoma in certain adult patients [4].
How is Proleukin administered?
Proleukin is typically administered intravenously (IV) in a hospital setting by healthcare professionals due to the potential for severe side effects. High-dose IL-2 therapy requires careful patient monitoring [3].
What are the potential side effects of Proleukin treatment?
High-dose Proleukin therapy can cause serious side effects, including low blood pressure, fluid retention, flu-like symptoms, fatigue, and organ damage. Due to these potential toxicities, patients are closely monitored in a hospital environment during treatment [3].
What is the manufacturer of Proleukin?
Proleukin was originally developed by Chiron Corporation, which was later acquired by Novartis [5].
Sources:
[1] https://www.goodrx.com/proleukin
[2] https://www.cbsnews.com/news/patient-shares-her-cancer-treatment-bill-shock/
[3] https://www.cancer.gov/types/skin/skin-cancer-treatment/melanoma
[4] https://www.cancer.gov/publications/drug-digest/descript-aldesleukin
[5] https://www.ncbi.nlm.nih.gov/books/NBK549588/